Aktienanalyse zu Maze Therapeutics Inc (MAZE)MAZEMaze Therapeutics Inc

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target. It operates in the Healthcare sector.

Maze Therapeutics is a good buy right now, with a current price of $31.01 and a strong analyst price target of $50 from Citi, indicating a potential upside of 61.5%. The RSI is at 64.121, suggesting bullish momentum. However, the main risk is the negative earnings per share (EPS) forecast of -0.7800 for the next earnings date on November 5, 2026.